A naukri.com initiative
Bioengineer
8h
305
Image Credit: Bioengineer
Platelet-Albumin-Bilirubin Predicts Hepatitis B Liver Cancer Survival
- The platelet-albumin-bilirubin (PALBI) score has emerged as a superior predictor of long-term survival for hepatitis B-associated hepatocellular carcinoma (HCC) patients post-hepatic resection compared to the traditional albumin-bilirubin (ALBI) grade.
- PALBI integrates platelet counts with albumin and bilirubin levels, offering a more comprehensive assessment of hepatic reserve and disease severity in HCC patients.
- A study by Yang et al. involving 1,005 hepatitis B-induced HCC patients undergoing liver resection demonstrated PALBI's higher predictive accuracy for overall survival compared to ALBI.
- PALBI showed superior discriminative power with an area under the curve (AUC) of 0.618 for overall survival, surpassing ALBI's AUC of 0.522.
- PALBI and ALBI were both independent prognostic factors for overall survival, but PALBI exhibited a tighter confidence interval and stronger p-value, enhancing its predictive reliability.
- PALBI also showed significant association with disease-free survival, indicating its relevance in anticipating tumor recurrence post-surgery.
- PALBI effectively segregated patients into distinct prognostic groups across different Barcelona Clinic Liver Cancer (BCLC) stages, offering refined clinical staging over ALBI.
- The inclusion of platelets in the PALBI score reflects their multifaceted roles in liver disease and aligns with emerging evidence on thrombocytopenia's impact on HCC prognosis.
- PALBI's accessibility, cost-effectiveness, and enhanced prognostic accuracy suggest its potential for widespread adoption in liver cancer management algorithms, particularly in resource-limited settings.
- The study's large sample size and longitudinal insight underscore PALBI's role in refining prognosis and tailoring personalized care for hepatitis B-induced HCC patients post-surgical resection.
Read Full Article
18 Likes
For uninterrupted reading, download the app